RxDoctor Payments Data

Debra Rodriguez

Adult Health · Pocatello, IDNPI 1275836157

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $477 of the $557 with a category attached, or 85.6%. 18 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 24.9% of the total.

$557in general payments, 2019–2025

Across 25 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$139
  • Harmony Biosciences LLC$54
  • AstraZeneca$49
  • Johnson & Johnson$41
  • Jazz Pharmaceuticals Inc.$32
  • E.r. Squibb & Sons, L.L.C.$29
  • plus $213 from 12 others

What the payments were for

  • Food & beverage$47786%
  • Education$8014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$557 in reported general payments places this provider in the 55th percentile of 38 adult health providers in Idaho.

See all adult health providers in Idaho

Medicare billing

Part B allowed, 2024
$14,752
Medicare patients
149
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$81,346
Spiriva RespimatTiotropium Bromide84$46,272
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$19,035
EliquisApixaban16$13,870
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$12,948
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$10,419
SymbicortBudesonide/Formoterol Fumarate24$5,637
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$4,780
Albuterol Sulfate HfaAlbuterol Sulfate172$4,182
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$3,343
Ventolin HfaAlbuterol Sulfate27$1,927
BreynaBudesonide/Formoterol Fumarate26$786
Montelukast Sodium56$602
Potassium Chloride21$359
Levalbuterol Tartrate HfaLevalbuterol Tartrate20$279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$23$91,765124 claims
AstraZenecaBreztri Aerosphere, Symbicort$49$24,67254 claims
PfizerEliquis$11$13,87016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 38 adult health providers in Idaho.

Other adult health in Pocatello

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →